CANNAINVESTOR Magazine February / March 2017 - Page 40


Our monthly review of select companies from past articles:

Each of those companies has had excellent news recently but three are specifically worth mentioning. Aphria, Inc. has been conditionally approved for up-listing to the TSX. TBP’s share price reached a high of $1.48 on February 15th (ie: a $15K investment less than one year ago reached a $1.48M valuation!). The Tinley Beverage Company’s website for its THC drinks ( has a “Now Accepting Patients” section dedicated for residents in California and “certain out of state” residents to register as well as announcing additional stores where Hemplify will be sold.


The focus on the January article was on Diversification including companies that do not touch the plant and/or have revenue streams outside of the cannabis sector. This month’s case study features two such companies that have recently signed a letter of intent to finalize a 50/50 Joint Venture: Lexaria Bioscience Corp. (CSE:LXX; OTC:LXRP) and Neutriscri International, Inc. (TSXV:NU; OTC:NRXCF).

Lexaria BioScience Corp. (Lexaria) Highlights

Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also masking taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.